Loading stock data…
ASBP
$0.21-0.01 (-4.11%)
Market ClosedLast close May 1
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aspire Biopharma Holdings, Inc. in the Healthcare sector is trading at $0.21. The stock is currently near its 52-week low of $0.16, remaining 97.3% below its 200-day moving average. Technical signals show oversold RSI of 12 and bearish MACD signal, explaining why ASBP maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 12) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.21
Potential Upside
5%
Whystock Fair Value$0.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
383.93%
Volume
Today's trading volume
4.71M
Recent News
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages
Aspire Biopharma (ASBP) wholly owned subsidiary, Buzz Bomb Caffeine Company, announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets. The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the L
Aspire files patent application for clopidogrel sublingual powder formulation
Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercializ
BC-Most Active Stocks
Nu Holdings Ltd. 35,303,567 16.69
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback
Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) is one of the best penny stocks under $1 to buy now. On July 9, Aspire Biopharma Holdings announced positive initial consumer feedback for its new sublingual pre-workout supplement, called BUZZ BOMB. The product features 50mg of caffeine and provides sustained energy and mental focus to athletes and fitness enthusiasts, […]
Aspire Biopharma provides development update on BUZZ BOMB supplement
Aspire Biopharma (ASBP) announced the brand name BUZZ BOMB and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential. Aspire has commenced initial production of BUZZ BOMB, its single serving pre-workout caffeine supplement utilizing Aspire’s patent-pending and proprietary sublingual delivery technology